These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 18189290)

  • 1. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004.
    Brown M; Tsodikov A; Bauer KR; Parise CA; Caggiano V
    Cancer; 2008 Feb; 112(4):737-47. PubMed ID: 18189290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.
    Bauer KR; Brown M; Cress RD; Parise CA; Caggiano V
    Cancer; 2007 May; 109(9):1721-8. PubMed ID: 17387718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA; Bauer KR; Brown MM; Caggiano V
    Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base.
    Killelea BK; Yang VQ; Wang SY; Hayse B; Mougalian S; Horowitz NR; Chagpar AB; Pusztai L; Lannin DR
    J Clin Oncol; 2015 Dec; 33(36):4267-76. PubMed ID: 26598753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age-specific incidence of breast cancer subtypes: understanding the black-white crossover.
    Clarke CA; Keegan TH; Yang J; Press DJ; Kurian AW; Patel AH; Lacey JV
    J Natl Cancer Inst; 2012 Jul; 104(14):1094-101. PubMed ID: 22773826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in California.
    Parise C; Caggiano V
    Cancer Epidemiol; 2014 Oct; 38(5):556-62. PubMed ID: 25172158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic features of breast cancer differ between women in the Democratic Republic of Congo and Belgium.
    Luyeye Mvila G; Batalansi D; Praet M; Marchal G; Laenen A; Christiaens MR; Brouckaert O; Ali-Risasi C; Neven P; Van Ongeval C
    Breast; 2015 Oct; 24(5):642-8. PubMed ID: 26279132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.
    Lund MJ; Trivers KF; Porter PL; Coates RJ; Leyland-Jones B; Brawley OW; Flagg EW; O'Regan RM; Gabram SG; Eley JW
    Breast Cancer Res Treat; 2009 Jan; 113(2):357-70. PubMed ID: 18324472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneity of breast cancer subtypes and survival among Hispanic women with invasive breast cancer in California.
    Banegas MP; Tao L; Altekruse S; Anderson WF; John EM; Clarke CA; Gomez SL
    Breast Cancer Res Treat; 2014 Apr; 144(3):625-34. PubMed ID: 24658879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer.
    Chen L; Cook LS; Tang MT; Porter PL; Hill DA; Wiggins CL; Li CI
    Breast Cancer Res Treat; 2016 Jun; 157(3):545-54. PubMed ID: 27220749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological characteristics of triple-negative invasive mammary carcinomas in African-American versus Caucasian women.
    Tawfik O; Davis K; Kimler BF; Davis MK; Hull S; Fan F; Khan QJ; O'Dea AP; Thomas P
    Ann Clin Lab Sci; 2010; 40(4):315-23. PubMed ID: 20947804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ.
    Liu Y; West R; Weber JD; Colditz GA
    Cancer; 2019 Sep; 125(18):3225-3233. PubMed ID: 31120565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disparities in race/ethnicity and socioeconomic status: risk of mortality of breast cancer patients in the California Cancer Registry, 2000-2010.
    Parise CA; Caggiano V
    BMC Cancer; 2013 Oct; 13():449. PubMed ID: 24083624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.
    Puig-Vives M; Sánchez MJ; Sánchez-Cantalejo J; Torrella-Ramos A; Martos C; Ardanaz E; Chirlaque MD; Perucha J; Díaz JM; Mateos A; Machón M; Marcos-Gragera R
    Gynecol Oncol; 2013 Sep; 130(3):609-14. PubMed ID: 23747837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.
    Brown M; Bauer K; Pare M
    Breast Cancer Res Treat; 2010 Feb; 120(1):217-27. PubMed ID: 19629680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent breast cancer trends among Asian/Pacific Islander, Hispanic, and African-American women in the US: changes by tumor subtype.
    Hausauer AK; Keegan TH; Chang ET; Clarke CA
    Breast Cancer Res; 2007; 9(6):R90. PubMed ID: 18162138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The epidemiology of triple-negative breast cancer, including race.
    Trivers KF; Lund MJ; Porter PL; Liff JM; Flagg EW; Coates RJ; Eley JW
    Cancer Causes Control; 2009 Sep; 20(7):1071-82. PubMed ID: 19343511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Racial/Ethnic Disparities in Survival after Breast Cancer Diagnosis by Estrogen and Progesterone Receptor Status: A Pooled Analysis.
    John EM; McGuire V; Kurian AW; Koo J; Shariff-Marco S; Gomez SL; Cheng I; Keegan THM; Kwan ML; Bernstein L; Vigen C; Wu AH
    Cancer Epidemiol Biomarkers Prev; 2021 Feb; 30(2):351-363. PubMed ID: 33355191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country.
    Subramaniam S; Bhoo-Pathy N; Taib NA; Tan GH; See MH; Jamaris S; Ho GF; Looi LM; Yip CH
    World J Surg; 2015 Oct; 39(10):2450-8. PubMed ID: 26138872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States.
    Elledge RM; Clark GM; Chamness GC; Osborne CK
    J Natl Cancer Inst; 1994 May; 86(9):705-12. PubMed ID: 7908990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.